Bachem (BANB) CMD 2024 summary

Strategic Vision and Market Overview

• Strategic focus on peptides and oligonucleotides (TIDES) as active pharmaceutical ingredients, leveraging innovation and long-term pharma partnerships.

• Positioned as a leading global CDMO with broad capabilities, robust late-stage clinical pipeline, and a strong global network.

• Market dynamics driven by disruptive changes in GLP-1, diabetes, obesity, and cancer, fueling surging demand and capacity needs.

• The peptide and oligonucleotide market is expanding rapidly, with over 1,100 peptide and 700 oligonucleotide projects in the pipeline.

• Annual sales reached CHF 577.3 million in 2023, with over 2,000 employees worldwide.

Capacity Expansion and Operational Execution

• Major capacity expansion underway with Building K and Sisslerfeld, designed for large-scale demand, with Building K's first unit online in 2025 and Sisslerfeld planned by decade's end.

• Shift from gradual to rapid, large-scale capacity ramp-up, with significant pre-launch bookings for new facilities.

• Capacity utilization across the network is close to 100%, with further growth expected from new and existing sites.

• Strengthening management and evolving to an integrated global GMP network to support transformation and scalability.

• High utilization of Building K is critical to achieving the CHF 1 billion revenue target by 2026.

Innovation and Technology Leadership

• Over 40 technology innovation projects are active, including green chemistry, continuous chromatography, and tag-assisted synthesis, with one-third in partnership with customers or academia.

• Innovation in solid supports, process R&D, and equipment aims to improve yields, sustainability, and scalability.

• Know-how transfer from peptides to oligonucleotides addresses future scale-up challenges.

• New technologies are being integrated into both new and existing sites to ensure process transferability and operational excellence.

• Prepared to manufacture complex dual, triple, and quadruple agonist peptides at scale.